Genedrive, a point-of-care pharmacogenetic testing company within the FTSE AIM All Share Index, has continued to build momentum for its rapid genetic test for newborns. On 12 October 2026 the company announced that the National Institute for Health and Care Research had published a case study highlighting its MT-RNR1 test, which estimated that national implementation could save the NHS about 5 million pounds a year. The news followed a run of adoption announcements in the UK and abroad over the summer.

What the company does

Genedrive develops rapid genetic tests designed to be used near the patient rather than in a central laboratory. Its MT-RNR1 test identifies newborns carrying a genetic variant that puts them at risk of hearing loss if they are given certain antibiotics, allowing clinicians to choose an alternative treatment quickly. Its second product, a CYP2C19 test, is a further pharmacogenetic assay that has been the subject of NHS implementation studies. The MT-RNR1 work has been developed with the University of Manchester and Manchester University NHS Foundation Trust.

Latest developments

The NIHR case study adds to a series of milestones. In June 2026 the company said the Manchester NHS trust had moved MT-RNR1 testing into business-as-usual use, and it signed a CYP2C19 agreement with Thermo Fisher Scientific. In early August it announced a new UK clinical guideline for MT-RNR1 testing and implementation of the test in the Netherlands, and on 11 August it reported completion of patient recruitment for its PALOH-UK study. On 10 September the company said Welsh hospitals had extended routine MT-RNR1 testing.

There have also been several board changes, with appointments announced in July and August 2026. The company presented to investors through ShareSoc in September.

Financial and Dividend picture

In a trading update on 13 July 2026, Genedrive said it expected Revenue of about 1.4 million pounds for the financial year ended 30 June 2026, up from roughly 1.0 million pounds the year before. It reported cash of about 3.0 million pounds at the year end. More than 13,000 newborns had been tested with the MT-RNR1 kit, and international revenue was expected to account for about a quarter of income, helped by a three-year commercial contract in the United Arab Emirates.

The company raised about 4.9 million pounds net through an Equity placing in March 2026. Genedrive is not profitable at its current scale and does not pay a dividend; its focus is on converting clinical evidence and guideline support into recurring sales.

Sector and index context

Pharmacogenetics, which uses a patient's genetic profile to guide prescribing, is attracting growing interest from health systems seeking to reduce adverse drug reactions and wasted treatment. Genedrive is one of a number of small diagnostics businesses in the FTSE AIM All Share Index, a group in which commercial traction and funding runway tend to drive sentiment.

Key risks

Revenue remains modest relative to the company's ambitions, and adoption across the NHS depends on procurement decisions made trust by trust, which can be slow. Further funding may be required before the Business becomes self-sustaining, raising the possibility of dilution. Competition from laboratory-based genetic testing and alternative technologies is another factor, as is the pace at which international markets take up the tests.

What to watch next

Investors will look for the full-year results for the year to June 2026, wider NHS commissioning of MT-RNR1 testing following the new clinical guideline, outcomes from CYP2C19 implementation studies and the PALOH-UK programme, and progress in international markets. The extent to which the estimated NHS savings translate into national adoption will be a key test for the business.